WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 564061
CAS#: 35954-65-5 (6S-isomer)
Description: FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival. In particular, in a model of Triple Negative Breast Cancer (TNBC) cells, MDA-MB-231, these effects are correlated to FR054-dependent reduction of both N- and O-glycosylation level that cause also a strong reduction of cancer cell adhesion and migration. . Note: The correct structure for FR054 is CAS#35954-65-5 which is the 6S-isomer. Some vendors are selling wrong structure for FAR054 (the incorrect structure has CAS#10378-06-0, which is the 6R-isomer)
MedKoo Cat#: 564061
CAS#: 35954-65-5 (6S-isomer)
Chemical Formula: C14H19NO8
Exact Mass: 329.1111
Molecular Weight: 329.31
Elemental Analysis: C, 51.06; H, 5.82; N, 4.25; O, 38.87
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: FR054; FR-054; FR 054
IUPAC/Chemical Name: 5H-Pyrano[3,2-d]oxazole-6,7-diol, 5-[(acetyloxy)methyl]-3a,6,7,7a-tetrahydro-2-methyl-, diacetate (ester), (3aR,5R,6S,7R,7aR)-
InChi Key: WZFQZRLQMXZMJA-KSTCHIGDSA-N
InChi Code: InChI=1S/C14H19NO8/c1-6-15-11-13(22-9(4)18)12(21-8(3)17)10(5-19-7(2)16)23-14(11)20-6/h10-14H,5H2,1-4H3/t10-,11-,12-,13-,14+/m1/s1
SMILES Code: CC1=N[C@@]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2)([H])[C@@]2([H])O1
Appearance: Oily liquid
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined.
Shelf Life: >3 years if stored properly
Drug Formulation: To be determined.
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 329.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Ricciardiello F, Bergamaschi L, De Vitto H, Gang Y, Zhang T, Palorini R, Chiaradonna F. Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor. Cells. 2021 Feb 18;10(2):431. doi: 10.3390/cells10020431. PMID: 33670598; PMCID: PMC7923121.
2: Ricciardiello F, Gang Y, Palorini R, Li Q, Giampà M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T, Zhao Y, Chiaradonna F. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene. 2020 May;39(20):4103-4117. doi: 10.1038/s41388-020-1260-1. Epub 2020 Mar 31. PMID: 32235891.
3: Ricciardiello F, Votta G, Palorini R, Raccagni I, Brunelli L, Paiotta A, Tinelli F, D'Orazio G, Valtorta S, De Gioia L, Pastorelli R, Moresco RM, La Ferla B, Chiaradonna F. Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis. Cell Death Dis. 2018 Mar 7;9(3):377. doi: 10.1038/s41419-018-0405-4. PMID: 29515119; PMCID: PMC5841296.